Jochen Schmitt1,2, Susanne Abraham3, Freya Trautmann1, Victoria Stephan1, Regina Fölster-Holst4, Bernhard Homey5, Thomas Bieber6, Natalija Novak6, Michael Sticherling7, Matthias Augustin8, Andreas Kleinheinz9, Peter Elsner10, Stephan Weidinger4, Thomas Werfel11. 1. Center for Evidence-based Health Care (ZEGV), Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany. 2. University Allergy Center (UAC), Carl Gustav Carus University Medical Center, TU Dresden, Dresden, Germany. 3. Department of Dermatology, Carl Gustav Carus University Medical Center, TU Dresden, Dresden, Germany. 4. Department of Dermatology, Venereology, and Allergology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. 5. Department of Dermatology, University Hospital Düsseldorf, Düsseldorf, Germany. 6. Department of Dermatology and Allergology, University Hospital Bonn, Bonn, Germany. 7. Department of Dermatology, University Hospital Erlangen, Erlangen, Germany. 8. Institute for Health Services Research in Dermatology and Nursing, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 9. Department of Dermatology, Elbe Medical Center, Buxtehude, Germany. 10. Department of Dermatology, University Hospital Jena, Jena, Germany. 11. Department of Dermatology, Allergology, and Venereology, Hanover Medical School, Hanover, Germany.
Abstract
BACKGROUND: The goal of clinical registries is to document the use and effectiveness of therapeutic interventions under real-life conditions. They are an indispensable prerequisite of evidence-based health care. METHODS: Initiated in 2011, the German Atopic Dermatitis Registry TREATgermany is the first registry of patients with severe atopic dermatitis worldwide. Adults with severe atopic dermatitis (current/prior systemic antiinflammatory treatment and/or objective SCORAD ≥ 40) are prospectively followed over the course of 24 months. Employed treatment modalities are documented, and validated measuring tools are used to assess clinical disease severity (EASI, objective SCORAD), quality of life (DLQI), symptoms (POEM), global disease severity, as well as patient satisfaction. Herein, we describe the characteristics, therapeutic selection, and effectiveness of systemic antiinflammatory treatments of patients enrolled in the registry until October 2014. RESULTS: Overall, 78 individuals (mean age 39 years, 61 % men) were enrolled at five recruitment centers. Patients frequently made use of inpatient and outpatient services. Not only was cyclosporine the most frequently administered systemic treatment, but also the most effective (EASI 50 response rate 51 %; EASI 75 response rate 34 % at 12 weeks). Azathioprine, methotrexate, oral prednisolone, mycophenolate, alitretinoin, and leflunomide were also used in some patients. CONCLUSIONS: The present analysis of the German Atopic Dermatitis Registry provides important data with respect to current medical care of adults with severe atopic dermatitis in Germany. It shows the high disease burden, the benefits of current treatment options, and the need for additional effective and safe long-term treatment options.
BACKGROUND: The goal of clinical registries is to document the use and effectiveness of therapeutic interventions under real-life conditions. They are an indispensable prerequisite of evidence-based health care. METHODS: Initiated in 2011, the German Atopic Dermatitis Registry TREATgermany is the first registry of patients with severe atopic dermatitis worldwide. Adults with severe atopic dermatitis (current/prior systemic antiinflammatory treatment and/or objective SCORAD ≥ 40) are prospectively followed over the course of 24 months. Employed treatment modalities are documented, and validated measuring tools are used to assess clinical disease severity (EASI, objective SCORAD), quality of life (DLQI), symptoms (POEM), global disease severity, as well as patient satisfaction. Herein, we describe the characteristics, therapeutic selection, and effectiveness of systemic antiinflammatory treatments of patients enrolled in the registry until October 2014. RESULTS: Overall, 78 individuals (mean age 39 years, 61 % men) were enrolled at five recruitment centers. Patients frequently made use of inpatient and outpatient services. Not only was cyclosporine the most frequently administered systemic treatment, but also the most effective (EASI 50 response rate 51 %; EASI 75 response rate 34 % at 12 weeks). Azathioprine, methotrexate, oral prednisolone, mycophenolate, alitretinoin, and leflunomide were also used in some patients. CONCLUSIONS: The present analysis of the German Atopic Dermatitis Registry provides important data with respect to current medical care of adults with severe atopic dermatitis in Germany. It shows the high disease burden, the benefits of current treatment options, and the need for additional effective and safe long-term treatment options.
Authors: F M Vermeulen; L A A Gerbens; A L Bosma; C J Apfelbacher; A D Irvine; B W M Arents; S Barbarot; M Deleuran; L F Eichenfield; A Manca; J Schmitt; C Vestergaard; D Wall; S Weidinger; M A Middelkamp-Hup; P I Spuls; C Flohr Journal: Br J Dermatol Date: 2019-06-23 Impact factor: 9.302
Authors: L von Kobyletzki; N Ballardini; D Henrohn; M P Neary; G Ortsäter; K Geale; A Rieem Dun; I Lindberg; A De Geer; P Neregård; A Cha; J C Cappelleri; W Romero; J P Thyssen Journal: J Eur Acad Dermatol Venereol Date: 2022-05-18 Impact factor: 9.228
Authors: A M Drucker; K Eyerich; M S de Bruin-Weller; J P Thyssen; P I Spuls; A D Irvine; G Girolomoni; S Dhar; C Flohr; D F Murrell; A S Paller; E Guttman-Yassky Journal: Br J Dermatol Date: 2018-01-28 Impact factor: 9.302